Skip to main content

METODOS AVANZADOS EN ESTUDIOS DE SEGUIMIENTO: DISEÑO DE ENSAYOS CLINICOS, DATOS LONGITUDINALES Y CENSURA EN UN INTERVALO

MTM2012-38067-C02-01

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Nacional de Proyectos de Investigación Fundamental
Subprogram Subprograma de Proyectos de Investigación Fundamental no Orientada
Call Proyectos I+D
Call year 2012
State Plan 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Management unit Secretaría de Estado de Investigación, Desarrollo e Innovación
Beneficiary centre UNIVERSITAT POLITECNICA DE CATALUNYA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Potential Role of (-)-Epigallocatechin-3-Gallate (EGCG) in the Secondary Prevention of Alzheimer Disease

  • Xicota Vila, Laura, 1987-
  • Rodríguez-Morató, Jose, 1987-
  • Dierssen, Mara
  • Torre Fornell, Rafael de la
Medical advances in the last decades have increased the average life expectancy, but also the incidence and prevalence of age-associated neurodegenerative diseases. Alzheimer's disease (AD) is one of the most common neurodegenerative diseases and the most prevalent type of dementia. A plethora of different mechanisms contribute to AD, among which oxidative stress plays a key role in its development and progression. So far, there are no pharmacological treatments available and the current medications are mainly symptomatic. In the last years, dietary polyphenols have gained research attention due to their interesting biological activities, and more specifically their antioxidant properties. (-)- Epigallocatechin-3-gallate (EGCG) is a natural flavanol that has been extensively studied regarding its potential effects in AD. In this review we present the current in vitro and in vivo experimentation regarding the use of EGCG in AD. We also review the complex mechanisms of action of EGCG, not only limited to its antioxidant activity, which may explain its beneficial health effects., This work was supported by grants, donations and agreements from Fondation Jérôme Lejeune (Paris, France), Instituto de Salud Carlos III FEDER, (PI11/00744), MINECO (SAF2010- 19434, MTM2012-38067-C02-01 and SAF2013-49129-C1- R), EU (Era Net Neuron PCIN-2013-060) co-financed by European Regional Development Fund, DIUE de la Generalitat de Catalunya (SGR 2009/1450, SGR 2014/464 SGR 2014/1125). We acknowledge support of the Spanish Ministry of Economy and Competitiveness, ‘Centro de Excelencia Severo Ochoa 2013-2017’, SEV-2012-0208.Jose Rodríguez-Morató was supported by a FI-DGR 2013 predoctoral fellowship from the Generalitat de Catalunya.
UPCommons. Portal del coneixement obert de la UPC
Publication Contribución de congreso (ConferenceOutput)

A geometric approach to dense Cayley digraphs of finite Abelian groups

  • Aguiló Gost, Francisco de Asis L.|||0000-0003-1572-8486
  • Fiol Mora, Miquel Àngel|||0000-0003-1337-4952
  • Pérez Mansilla, Sonia|||0000-0001-9831-1066
We give a method for constructing infinite families of dense (or eventually likely dense) Cayley digraphs of finite Abelian groups. The diameter of the digraphs is obtained by means of the related {\em minimum distance diagrams}. A {\em dilating} technique for these diagrams, which can be used for any degree of the digraph, is applied to generate the digraphs of the family. Moreover, two infinite families of digraphs with distinguished metric properties will be given using these methods. The first family contains digraphs with asymptotically large ratio between the order and the diameter as the degree increases (moreover it is the first known asymptotically dense family). The second family, for fixed degree $d=3$, contains digraphs with the current best known density., Peer Reviewed
UPCommons. Portal del coneixement obert de la UPC
Publication Artículo científico (JournalArticle)

Monotherapy with boosted PIs as an ART simplification strategy in clinical practice

  • Santos, Jose R.
  • Llibre, Josep M.
  • Berrio Galan, Daniel
  • Bravo, Isabel
  • Miranda, Cristina
  • Pérez Álvarez, Susana|||0000-0003-2724-5131
  • Pérez Álvarez, Nuria|||0000-0001-6582-1553
  • Paredes Deirós, Roger
  • Clotet Sala, Bonaventura
  • Molto Marhuenda, Jose
Background: Data on the efficacy of simplifying therapy using darunavir/ritonavir and lopinavir/ritonavir monotherapy in clinical practice remain limited.; Methods: A retrospective single-centre study including patients initiating darunavir/ritonavir or lopinavir/ritonavir monotherapy with a plasma HIV-1 viral load (pVL) <50 copies/mL and at least one subsequent follow-up visit. The primary endpoint was the percentage of patients remaining free of virological failure (VF; defined as a confirmed pVL >50 copies/mL or as any change in the regimen after a single determination with a pVL >50 copies/mL) during the follow-up. We also evaluated the percentage of patients remaining free of treatment failure (TF; defined as VF or the early discontinuation of monotherapy for any reason) and compared the effectiveness of the two regimens. Effectiveness was evaluated using cumulative survival analysis (at Weeks 48 and 96). Factors associated with VF and TF were analysed using Cox regression.; Results: A total of 522 patients were included (309 receiving lopinavir/ritonavir and 213 receiving darunavir/ritonavir). The median follow-up was 64.3 (30.5-143.0) weeks. The percentage of patients free of VF and TF was 94% (95% CI 91%-96%) and 79% (95% CI 75%-82%) at 48 weeks, respectively, and 86% (95% CI 81%-89%) and 62% (95% CI 57%-67%) at 96 weeks, respectively. The risk of VF was similar for the two regimens (HR = 1.0, 95% CI 0.6-1.8; P = 0.962). Lopinavir/ritonavir monotherapy was associated with a 1.5-fold greater risk of TF (95% CI 1.1-2.1; P = 0.012) and a 2.3-fold greater risk of discontinuation of therapy due to adverse events (95% CI 1.3-3.9; P = 0.003).; Conclusions: The virological efficacy of darunavir/ritonavir and lopinavir/ritonavir monotherapy is high in clinical practice. Treatment discontinuation due to safety issues is more frequent with lopinavir/ritonavir., This study was supported in part by grants from Lluita contra la SIDA Foundation (Barcelona, Spain), the Spanish AIDS Network ‘Red Temática Cooperativa de Investigación en SIDA’ (RIS, RD06/0006), NEAT (European AIDS Treatment Network), Ministerio de Economía y Competitividad of Spain (MTM2012-38067-C02-01) and GRBIO (Grup de Recerca en Bioestadística i Bioinformàtica; 2014 SGR 464). The funders had no role in study design, data collection and analysis, the decision to publish or drafting of the manuscript., Peer Reviewed
UPCommons. Portal del coneixement obert de la UPC
Publication Artículo científico (JournalArticle)

FARMS: a new algorithm for variable selection

  • Pérez Álvarez, Susana|||0000-0003-2724-5131
  • Gómez Melis, Guadalupe|||0000-0003-4252-4884
  • Brander, Christian
Large datasets including an extensive number of covariates are generated these days in many different situations, for instance, in detailed genetic studies of outbreed human populations or in complex analyses of immune responses to different infections. Aiming at informing clinical interventions or vaccine design, methods for variable selection identifying those variables with the optimal prediction performance for a specific outcome are crucial. However, testing for all potential subsets of variables is not feasible and alternatives to existing methods are needed. Here, we describe a new method to handle such complex datasets, referred to as FARMS, that combines forward and all subsets regression for model selection. We apply FARMS to a host genetic and immunological dataset of over 800 individuals from Lima (Peru) and Durban (South Africa) who were HIV infected and tested for antiviral immune responses. This dataset includes more than 500 explanatory variables: around 400 variables with information on HIV immune reactivity and around 100 individual genetic characteristics. We have implemented FARMS in R statistical language and we showed that FARMS is fast and outcompetes other comparable commonly used approaches, thus providing a new tool for the thorough analysis of complex datasets without the need for massive computational infrastructure., Peer Reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Monotherapy with boosted PIs as an ART simplification strategy in clinical practice

  • Santos, Jose R.
  • Llibre, Josep M.
  • Berrio Galan, Daniel
  • Bravo, Isabel
  • Miranda, Cristina
  • Pérez Álvarez, Susana
  • Pérez Álvarez, Nuria
  • Paredes Deirós, Roger
  • Clotet Sala, Bonaventura
  • Molto Marhuenda, Jose
Background: Data on the efficacy of simplifying therapy using darunavir/ritonavir and lopinavir/ritonavir monotherapy in clinical practice remain limited.; Methods: A retrospective single-centre study including patients initiating darunavir/ritonavir or lopinavir/ritonavir monotherapy with a plasma HIV-1 viral load (pVL) <50 copies/mL and at least one subsequent follow-up visit. The primary endpoint was the percentage of patients remaining free of virological failure (VF; defined as a confirmed pVL >50 copies/mL or as any change in the regimen after a single determination with a pVL >50 copies/mL) during the follow-up. We also evaluated the percentage of patients remaining free of treatment failure (TF; defined as VF or the early discontinuation of monotherapy for any reason) and compared the effectiveness of the two regimens. Effectiveness was evaluated using cumulative survival analysis (at Weeks 48 and 96). Factors associated with VF and TF were analysed using Cox regression.; Results: A total of 522 patients were included (309 receiving lopinavir/ritonavir and 213 receiving darunavir/ritonavir). The median follow-up was 64.3 (30.5-143.0) weeks. The percentage of patients free of VF and TF was 94% (95% CI 91%-96%) and 79% (95% CI 75%-82%) at 48 weeks, respectively, and 86% (95% CI 81%-89%) and 62% (95% CI 57%-67%) at 96 weeks, respectively. The risk of VF was similar for the two regimens (HR = 1.0, 95% CI 0.6-1.8; P = 0.962). Lopinavir/ritonavir monotherapy was associated with a 1.5-fold greater risk of TF (95% CI 1.1-2.1; P = 0.012) and a 2.3-fold greater risk of discontinuation of therapy due to adverse events (95% CI 1.3-3.9; P = 0.003).; Conclusions: The virological efficacy of darunavir/ritonavir and lopinavir/ritonavir monotherapy is high in clinical practice. Treatment discontinuation due to safety issues is more frequent with lopinavir/ritonavir., This study was supported in part by grants from Lluita contra la SIDA Foundation (Barcelona, Spain), the Spanish AIDS Network ‘Red Temática Cooperativa de Investigación en SIDA’ (RIS, RD06/0006), NEAT (European AIDS Treatment Network), Ministerio de Economía y Competitividad of Spain (MTM2012-38067-C02-01) and GRBIO (Grup de Recerca en Bioestadística i Bioinformàtica; 2014 SGR 464). The funders had no role in study design, data collection and analysis, the decision to publish or drafting of the manuscript., Peer Reviewed, Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

FARMS: a new algorithm for variable selection

  • Pérez Álvarez, Susana
  • Gómez Melis, Guadalupe
  • Brander, Christian
Large datasets including an extensive number of covariates are generated these days in many different situations, for instance, in detailed genetic studies of outbreed human populations or in complex analyses of immune responses to different infections. Aiming at informing clinical interventions or vaccine design, methods for variable selection identifying those variables with the optimal prediction performance for a specific outcome are crucial. However, testing for all potential subsets of variables is not feasible and alternatives to existing methods are needed. Here, we describe a new method to handle such complex datasets, referred to as FARMS, that combines forward and all subsets regression for model selection. We apply FARMS to a host genetic and immunological dataset of over 800 individuals from Lima (Peru) and Durban (South Africa) who were HIV infected and tested for antiviral immune responses. This dataset includes more than 500 explanatory variables: around 400 variables with information on HIV immune reactivity and around 100 individual genetic characteristics. We have implemented FARMS in R statistical language and we showed that FARMS is fast and outcompetes other comparable commonly used approaches, thus providing a new tool for the thorough analysis of complex datasets without the need for massive computational infrastructure., Peer Reviewed, Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Potential Role of (-)-Epigallocatechin-3-Gallate (EGCG) in the Secondary Prevention of Alzheimer Disease

  • Xicota Vila, Laura, 1987-
  • Rodríguez-Morató, Jose, 1987-
  • Dierssen, Mara
  • Torre Fornell, Rafael de la
Medical advances in the last decades have increased the average life expectancy, but also the incidence and prevalence of age-associated neurodegenerative diseases. Alzheimer's disease (AD) is one of the most common neurodegenerative diseases and the most prevalent type of dementia. A plethora of different mechanisms contribute to AD, among which oxidative stress plays a key role in its development and progression. So far, there are no pharmacological treatments available and the current medications are mainly symptomatic. In the last years, dietary polyphenols have gained research attention due to their interesting biological activities, and more specifically their antioxidant properties. (-)- Epigallocatechin-3-gallate (EGCG) is a natural flavanol that has been extensively studied regarding its potential effects in AD. In this review we present the current in vitro and in vivo experimentation regarding the use of EGCG in AD. We also review the complex mechanisms of action of EGCG, not only limited to its antioxidant activity, which may explain its beneficial health effects., This work was supported by grants, donations and agreements from Fondation Jérôme Lejeune (Paris, France), Instituto de Salud Carlos III FEDER, (PI11/00744), MINECO (SAF2010- 19434, MTM2012-38067-C02-01 and SAF2013-49129-C1- R), EU (Era Net Neuron PCIN-2013-060) co-financed by European Regional Development Fund, DIUE de la Generalitat de Catalunya (SGR 2009/1450, SGR 2014/464 SGR 2014/1125). We acknowledge support of the Spanish Ministry of Economy and Competitiveness, ‘Centro de Excelencia Severo Ochoa 2013-2017’, SEV-2012-0208.Jose Rodríguez-Morató was supported by a FI-DGR 2013 predoctoral fellowship from the Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publication Contribución de congreso (ConferenceOutput)

A geometric approach to dense Cayley digraphs of finite Abelian groups

  • Aguiló Gost, Francisco de Asis L.
  • Fiol Mora, Miquel Àngel
  • Pérez Mansilla, Sonia
We give a method for constructing infinite families of dense (or eventually likely dense) Cayley digraphs of finite Abelian groups. The diameter of the digraphs is obtained by means of the related {\em minimum distance diagrams}. A {\em dilating} technique for these diagrams, which can be used for any degree of the digraph, is applied to generate the digraphs of the family. Moreover, two infinite families of digraphs with distinguished metric properties will be given using these methods. The first family contains digraphs with asymptotically large ratio between the order and the diameter as the degree increases (moreover it is the first known asymptotically dense family). The second family, for fixed degree $d=3$, contains digraphs with the current best known density., Peer Reviewed, Postprint (author's final draft)
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

FARMS, A New Algorithm for Variable Selection

  • Pérez-Álvarez, Susana
  • Gómez Melis, Guadalupe|||0000-0003-4252-4884
  • Brander, Christian|||0000-0002-0548-5778
Large datasets including an extensive number of covariates are generated these days in many different situations, for instance, in detailed genetic studies of outbreed human populations or in complex analyses of immune responses to different infections. Aiming at informing clinical interventions or vaccine design, methods for variable selection identifying those variables with the optimal prediction performance for a specific outcome are crucial. However, testing for all potential subsets of variables is not feasible and alternatives to existing methods are needed. Here, we describe a new method to handle such complex datasets, referred to as FARMS, that combines forward and all subsets regression for model selection. We apply FARMS to a host genetic and immunological dataset of over 800 individuals from Lima (Peru) and Durban (South Africa) who were HIV infected and tested for antiviral immune responses. This dataset includes more than 500 explanatory variables: around 400 variables with information on HIV immune reactivity and around 100 individual genetic characteristics. We have implemented FARMS in R statistical language and we showed that FARMS is fast and outcompetes other comparable commonly used approaches, thus providing a new tool for the thorough analysis of complex datasets without the need for massive computational infrastructure.